Drug Interactions between Coenzyme Q10 and elvitegravir
This report displays the potential drug interactions for the following 2 drugs:
- Coenzyme Q10 (ubiquinone)
- elvitegravir
Interactions between your drugs
No interactions were found between Coenzyme Q10 and elvitegravir. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Coenzyme Q10
A total of 3 drugs are known to interact with Coenzyme Q10.
- Coenzyme q10 is in the drug class nutraceutical products.
- Coenzyme q10 is used to treat Dietary Supplementation.
elvitegravir
A total of 95 drugs are known to interact with elvitegravir.
- Elvitegravir is in the drug class integrase strand transfer inhibitor.
- Elvitegravir is used to treat HIV Infection.
Drug and food interactions
elvitegravir food
Applies to: elvitegravir
ADJUST DOSING INTERVAL: Food enhances the oral bioavailabilities of both elvitegravir and tenofovir. When a single dose of cobicistat/elvitegravir/emtricitabine/tenofovir (trade name Stribild) was given with a light meal (approximately 373 kcal; 20% fat), mean elvitegravir and tenofovir systemic exposures (AUCs) increased by 34% and 24%, respectively, relative to fasting conditions. When administered with a high-fat meal (approximately 800 kcal; 50% fat), the mean AUC of elvitegravir and tenofovir increased by 87% and 23%, respectively, relative to fasting conditions. The alterations in mean AUCs of cobicistat and emtricitabine were not clinically significant with either the light or high-fat meal.
MANAGEMENT: Cobicistat/elvitegravir/emtricitabine/tenofovir as a fixed-dose preparation should be administered once daily with food. Elvitegravir as a single-ingredient preparation should also be administered once daily with food.
References (2)
- (2012) "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences
- (2014) "Product Information. Vitekta (elvitegravir)." Gilead Sciences
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.